Extracellular vesicles(EVs)are lipid bilayer-enclosed vesicles released by cells.EVs encapsulate proteins and nucleic acids of their parental cell and efficiently deliver the cargo to recipient cells.These vesicles ac...Extracellular vesicles(EVs)are lipid bilayer-enclosed vesicles released by cells.EVs encapsulate proteins and nucleic acids of their parental cell and efficiently deliver the cargo to recipient cells.These vesicles act as mediators of intercellular communication and thus play a crucial role in various physiological and pathological processes.Moreover,EVs hold promise for clinical use.They have been explored as drug delivery vehicles,therapeutic agents,and targets for disease diagnosis.In the landscape of cancer research,while strides have been made in EV-focused cancer physiopathology,liquid biopsy,and drug delivery,the exploration of EVs as immunotherapeutic agents may not have seen substantial progress to date.Despite promising findings reported in cell and animal studies,the clinical translation of EV-based cancer immunotherapeutics encounters challenges.Here,we review the existing strategies used in EV-based cancer immunotherapy,aiming to propel the development of this emerging yet crucial field.展开更多
基金supported by the National Cancer Institute(grants R01CA230339 and R37CA255948).
文摘Extracellular vesicles(EVs)are lipid bilayer-enclosed vesicles released by cells.EVs encapsulate proteins and nucleic acids of their parental cell and efficiently deliver the cargo to recipient cells.These vesicles act as mediators of intercellular communication and thus play a crucial role in various physiological and pathological processes.Moreover,EVs hold promise for clinical use.They have been explored as drug delivery vehicles,therapeutic agents,and targets for disease diagnosis.In the landscape of cancer research,while strides have been made in EV-focused cancer physiopathology,liquid biopsy,and drug delivery,the exploration of EVs as immunotherapeutic agents may not have seen substantial progress to date.Despite promising findings reported in cell and animal studies,the clinical translation of EV-based cancer immunotherapeutics encounters challenges.Here,we review the existing strategies used in EV-based cancer immunotherapy,aiming to propel the development of this emerging yet crucial field.
